Literature DB >> 31036488

Mucoid Pseudomonas aeruginosa and regional inflammation in the cystic fibrosis lung.

Sankalp Malhotra1, Don Hayes2, Daniel J Wozniak3.   

Abstract

BACKGROUND: Pseudomonas aeruginosa is the prominent bacterial pathogen in the cystic fibrosis (CF) lung and contributes to significant morbidity and mortality. Though P. aeruginosa strains initially colonizing the CF lung have a nonmucoid colony morphology, they often mutate into mucoid variants that are associated with clinical deterioration. Both nonmucoid and mucoid P. aeruginosa variants are often co-isolated on microbiological cultures of sputum collected from CF patients. With regional variation in bronchiectasis, tissue damage, inflammation, and microbial colonization, lobar distribution of nonmucoid and mucoid P. aeruginosa variants may impact local microenvironments in the CF lung, but this has not been well-studied.
METHODS: We prospectively collected lobe-specific bronchoalveolar lavage (BAL) fluid from a CF patient cohort (n = 14) using a standardized bronchoscopic protocol where collection was performed in 6 lobar regions. The lobar BAL specimens were plated on P. aeruginosa-selective media and proinflammatory cytokines (IL-1, TNF, IL-6 and IL-8) were measured via cytokine array. Correlations between infecting P. aeruginosa variants (nonmucoid, mucoid, or mixed-variant populations), the lobar regions in which these variants were found, and regional proinflammatory cytokine concentrations were measured.
RESULTS: P. aeruginosa mucoid and nonmucoid variants were homogenously distributed throughout the CF lung. However, infection with mucoid variants (found within single- or mixed-variant populations) was associated with significantly greater regional inflammation. The upper and lower lobes of the CF lung did not exhibit differences in inflammatory cytokine concentrations.
CONCLUSIONS: Mucoid P. aeruginosa infection is a microbial determinant of regional inflammation within the CF lung.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Airway; Cystic fibrosis; Cytokines; Inflammation; Lung; Mucoid; Pseudomonas aeruginosa

Mesh:

Substances:

Year:  2019        PMID: 31036488      PMCID: PMC6815243          DOI: 10.1016/j.jcf.2019.04.009

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  58 in total

1.  Lower airway inflammation in infants with cystic fibrosis detected by newborn screening.

Authors:  David S Armstrong; Sarah M Hook; Kris M Jamsen; Gillian M Nixon; Rosemary Carzino; John B Carlin; Colin F Robertson; Keith Grimwood
Journal:  Pediatr Pulmonol       Date:  2005-12

2.  Pharmacokinetics/pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa biofilms.

Authors:  Wang Hengzhuang; Hong Wu; Oana Ciofu; Zhijun Song; Niels Høiby
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

3.  Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of upper-airway specimens can misrepresent lung microbiota.

Authors:  Amanda F Goddard; Benjamin J Staudinger; Scot E Dowd; Amruta Joshi-Datar; Randall D Wolcott; Moira L Aitken; Corinne L Fligner; Pradeep K Singh
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-07       Impact factor: 11.205

Review 4.  Pseudomonas aeruginosa biofilms in cystic fibrosis.

Authors:  Niels Høiby; Oana Ciofu; Thomas Bjarnsholt
Journal:  Future Microbiol       Date:  2010-11       Impact factor: 3.165

5.  Sequence diversity of the mucABD locus in Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  Alessandra Bragonzi; Lutz Wiehlmann; Jens Klockgether; Nina Cramer; Dieter Worlitzsch; Gerd Döring; Burkhard Tümmler
Journal:  Microbiology       Date:  2006-11       Impact factor: 2.777

6.  In situ growth rates and biofilm development of Pseudomonas aeruginosa populations in chronic lung infections.

Authors:  Lei Yang; Janus A J Haagensen; Lars Jelsbak; Helle Krogh Johansen; Claus Sternberg; Niels Høiby; Søren Molin
Journal:  J Bacteriol       Date:  2007-12-21       Impact factor: 3.490

7.  Distribution of early structural lung changes due to cystic fibrosis detected with chest computed tomography.

Authors:  Lauren S Mott; Judy Park; Catherine L Gangell; Nicholas H de Klerk; Peter D Sly; Conor P Murray; Stephen M Stick
Journal:  J Pediatr       Date:  2013-01-26       Impact factor: 4.406

8.  Inflammatory cytokines in cystic fibrosis lungs.

Authors:  T L Bonfield; J R Panuska; M W Konstan; K A Hilliard; J B Hilliard; H Ghnaim; M Berger
Journal:  Am J Respir Crit Care Med       Date:  1995-12       Impact factor: 21.405

9.  Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients.

Authors:  Thomas Bjarnsholt; Peter Østrup Jensen; Mark J Fiandaca; Jette Pedersen; Christine Rønne Hansen; Claus Bøgelund Andersen; Tacjana Pressler; Michael Givskov; Niels Høiby
Journal:  Pediatr Pulmonol       Date:  2009-06

10.  Phenotypic diversity within a Pseudomonas aeruginosa population infecting an adult with cystic fibrosis.

Authors:  Shawn T Clark; Julio Diaz Caballero; Mary Cheang; Bryan Coburn; Pauline W Wang; Sylva L Donaldson; Yu Zhang; Mingyao Liu; Shaf Keshavjee; Yvonne C W Yau; Valerie J Waters; D Elizabeth Tullis; David S Guttman; David M Hwang
Journal:  Sci Rep       Date:  2015-06-05       Impact factor: 4.379

View more
  11 in total

1.  The histone-like protein AlgP regulon is distinct in mucoid and nonmucoid Pseudomonas aeruginosa and does not include alginate biosynthesis genes.

Authors:  Ashley R Cross; Erika E Csatary; Vishnu Raghuram; Frances L Diggle; Marvin Whiteley; William M Wuest; Joanna B Goldberg
Journal:  Microbiology (Reading)       Date:  2020-09       Impact factor: 2.777

2.  Extracellular Vesicles from Pseudomonas aeruginosa Suppress MHC-Related Molecules in Human Lung Macrophages.

Authors:  David A Armstrong; Min Kyung Lee; Haley F Hazlett; John A Dessaint; Diane L Mellinger; Daniel S Aridgides; Gregory M Hendricks; Moemen A K Abdalla; Brock C Christensen; Alix Ashare
Journal:  Immunohorizons       Date:  2020-08-20

Review 3.  Airway immunometabolites fuel Pseudomonas aeruginosa infection.

Authors:  Sebastián A Riquelme; Alice Prince
Journal:  Respir Res       Date:  2020-12-10

4.  Comparative genome analysis of multidrug-resistant Pseudomonas aeruginosa JNQH-PA57, a clinically isolated mucoid strain with comprehensive carbapenem resistance mechanisms.

Authors:  Mingju Hao; Wanshan Ma; Xiutao Dong; Xiaofeng Li; Fang Cheng; Yujiao Wang
Journal:  BMC Microbiol       Date:  2021-05-01       Impact factor: 3.605

5.  The Impact of an Efflux Pump Inhibitor on the Activity of Free and Liposomal Antibiotics against Pseudomonas aeruginosa.

Authors:  Douweh Leyla Gbian; Abdelwahab Omri
Journal:  Pharmaceutics       Date:  2021-04-18       Impact factor: 6.321

Review 6.  The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update.

Authors:  Dan Reynolds; Marin Kollef
Journal:  Drugs       Date:  2021-11-07       Impact factor: 9.546

7.  Repurposing the Veterinary Antibiotic Apramycin for Antibacterial and Antibiofilm Activity Against Pseudomonas aeruginosa From Cystic Fibrosis Patients.

Authors:  Giovanni Di Bonaventura; Veronica Lupetti; Fabio Verginelli; Sara Giancristofaro; Rosemary Barbieri; Giovanni Gherardi; Arianna Pompilio
Journal:  Front Microbiol       Date:  2022-02-03       Impact factor: 5.640

Review 8.  The current landscape of microRNAs (miRNAs) in bacterial pneumonia: opportunities and challenges.

Authors:  Fan Zhang; Yunxin Zhou; Junying Ding
Journal:  Cell Mol Biol Lett       Date:  2022-08-19       Impact factor: 8.702

Review 9.  Pseudomonas aeruginosa: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors.

Authors:  Irene Jurado-Martín; Maite Sainz-Mejías; Siobhán McClean
Journal:  Int J Mol Sci       Date:  2021-03-18       Impact factor: 5.923

Review 10.  An Organ System-Based Synopsis of Pseudomonas aeruginosa Virulence.

Authors:  Charles D Morin; Eric Déziel; Jeff Gauthier; Roger C Levesque; Gee W Lau
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.